Arcus Biosciences, Inc. (RCUS) — Available-Data Snapshot

We don't publish a discounted-cash-flow fair value for Arcus Biosciences, Inc. (RCUS) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, RCUS trades at a recent price of $18.95, a market capitalisation of about $2,728,622,080, sitting 11% of the way up its 52-week range ($17.43–$31.73), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing RCUS's trading multiples against a sector benchmark. Here that gives P/B of 6.8× (cheaper than the peer median of 8.3×); P/S of 27.3× (richer than the peer median of 6.8×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. RCUS shows a price-to-book (P/B) of 6.75 and book value of $2.81 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. RCUS is in a down-trend (price below both its 50- and 200-day averages), trading -40.3% from its 52-week high. Over the past year the stock is -6.1%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.